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Abstract
Background: This article seeks to identify the role of databases in health policy. Access to
information and communication technologies has changed traditional relationships between the
state and professionals, creating new systems of surveillance and control. As a result, databases may
have a profound effect on controlling clinical practice.
Methods: We conducted three case studies to reconstruct the development and use of databases
as policy instruments. Each database was intended to be employed to control the use of one
particular pharmaceutical in the Netherlands (growth hormone, antiretroviral drugs for HIV and
Taxol, respectively). We studied the archives of the Dutch Health Insurance Board, conducted in-
depth interviews with key informants and organized two focus groups, all focused on the use of
databases both in policy circles and in clinical practice.
Results: Our results demonstrate that policy makers hardly used the databases, neither for cost
control nor for quality assurance. Further analysis revealed that these databases facilitated self-
regulation and quality assurance by (national) bodies of professionals, resulting in restrictive
prescription behavior amongst physicians.
Conclusion: The databases fulfill control functions that were formerly located within the policy
realm. The databases facilitate collaboration between policy makers and physicians, since they
enable quality assurance by professionals. Delegating regulatory authority downwards into a
network of physicians who control the use of pharmaceuticals seems to be a good alternative for
centralized control on the basis of monitoring data.
Background
Several authors have stressed the need for improving evi-
dence-based health policy [1-3]. One way of enabling
truly evidence based policy is claimed to be the use of
databases [4,5]. Where the results of clinical studies are
lacking or are insufficient – for example in when there is
uncertainty about the long-term effects of a specific tech-
nology – databases may be used to monitor the effective-
ness and safety of using these technologies in clinical
practice. In addition, monitoring can be used to produce
data about the appropriateness of care and associated
costs. In short, it is assumed that databases, particularly
those linked to electronic medical records, would enable
the long-term follow-up of patients, providing informa-
tion about the diffusion of pharmaceuticals in clinical
practice, their coverage and budget impact [6-8]. Several
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monitoring systems are hardly used [9,10]. Lehenkari and
Hyssalo, who studied a diabetes management system in
Finland were confronted by a 'graveyard' of databases.
From the 1980's on, 21 similar diabetes databases have
been developed in Finland to monitor the incidence of
retinopathy. Only four databases still exist (Lehenkari, J.
and S. Hyysalo, Interventions in the networks of power
and cooperative learning, submitted.). Likewise, Black
and Paine, who conducted a survey of clinical databases in
the UK, concluded that only a third of the databases had
been used for research purposes [11]. In addition, Pollitt
demonstrated in a recent literature review that the evi-
dence of active and systematic use of performance data for
policy purposes is limited [10]. However, considering the
efficacy of databases only in terms of their use for policy-
making may yield too limited a conceptual perspective.
Pollitt suggests that the regular production of perform-
ance information may be as important as the consump-
tion of these data [10]. Moreover, information
technologies such as databases may have profound effects
on the relation between clinicians, health-care managers,
insurers and policy makers, as traditional patterns of gov-
ernance seem to be challenged in the information age, cre-
ating new systems of surveillance and control [12-14].
According to Singh, information networks can be seen as
governance networks that "allow for different forms of
authority". Hence, databases may have a profound effect
on controlling clinical practice, e.g. in facilitating collabo-
ration between policy makers and physicians, even
though they are hardly used in policy making as such.
From the 1990's the Dutch Health Insurance Board (CVZ)
has been using clinical databases as instruments for evi-
dence-based health policy making [6-8]. In 2004, the
board of CVZ asked the Department of Health Policy and
Management to evaluate the use of the databases to
enforce policy measures, as the Board was dissatisfied
with the databases they already had set up to control the
use of a number of expensive drugs. According to them
these databases did not contain the data they needed. The
purpose of our study was to gain insight into the use of
existing databases and to advise the board on whether and
how they should use such databases to control the use of
pharmaceuticals. To this end we studied the use of data-
bases (both by policy makers and clinicians) for three
expensive pharmaceuticals.
Methods
We conducted a multiple case study. We selected three
databases CVZ supported. These three were intended to be
used to monitor the prescriptions of Taxol, growth hor-
mone and antiretroviral drugs for HIV. The Taxol database
was selected because CVZ saw it as a failure, while the
other two databases were seen as a relative success.
Although CVZ was not very satisfied with the content and
the use of the growth hormone databases and anti-HIV
database, they were at least seen as the best examples.
We started the case studies by reconstructing the develop-
ment and use of the databases on the basis of the records
of the CVZ. To study the use of the databases, we made an
overview of relevant policy questions that were supposed
to be answered with the data from the databases. In addi-
tion, we conducted 17 in-depth interviews with policy
makers, researchers and physicians to understand why the
databases were developed and how they were used or
expected to be used. After the interviews, we organized
two focus group sessions, which were conducted with a
moderator and two observers. The focus groups were
attended by physicians who developed and managed the
databases, staff members of CVZ, representatives of health
insurers and representatives of patient organizations. The
topic guide for the focus groups was based upon the doc-
uments and the individual interviews. It contained the fol-
lowing issues: the use of databases, relevant policy
questions and the possibilities to control the use of phar-
maceuticals. Both the interviews and the focus groups
were audio-taped and transcribed verbatim. The theoreti-
cal framework used to analyze the data was the sociotech-
nical perspective on IT [15,16]. This framework seeks to
understand the interaction between technology and soci-
ety. With this perspective we unraveled how the use of
databases shaped the way the use of pharmaceuticals is
controlled. We checked the results of our study with the
CVZ and the owners of the databases.
The context
In 2000, the Dutch government decided (after having
taken many and increasingly detailed policy measures
which did not have the expected cost reducing effects) to
delegate the responsibility to control the use of pharma-
ceuticals to health insurers and health professionals [17].
The government realized that it could not control the use
of and expenditure on pharmaceuticals exclusively
through laws and regulation, and developed a series of
new tools, such as protocols and databases, to promote
rational prescribing.
These developments have led to new styles of regulation,
of which conditional reimbursement is a good example.
The goal of conditional reimbursement is to promote
effective and efficient use of certain pharmaceuticals. For
this purpose, reimbursement of a drug is made condi-
tional on specific criteria or rules. For example, the appli-
cation may be restricted to specific categories of patients
or prescriptions may only be provided by authorized phy-
sicians. All drugs to which these conditions apply are
included in the so-called Health Insurance Fund (Provi-
sion of Pharmaceuticals) Regulation Appendix 2. CriteriaPage 2 of 6
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the need of specific expertise to ensure appropriate patient
selection [18]. The policy of conditional reimbursement
was and still is considered a promising approach to the
delivery of effective and efficient pharmaceutical care [19-
21].
The reimbursement of Growth hormone, Taxol and
antiretroviral drugs for HIV is conditional. They are only
reimbursed if physicians follow a specific protocol. The
reimbursement of the growth hormone and Taxol is also
restricted to specific categories of patients. Taxol, for
example, is only reimbursed for patients with ovarian or
mama carcinoma with metastasis. For growth hormone,
the first pharmaceutical that was labeled as an 'expensive
pharmaceutical', a third condition is set. Prior authoriza-
tion needs to be obtained from an expert committee
before it can be reimbursed [19].
Between 1998 and 2004, the board of CVZ advised the
Minster of Health seven times to provide reimbursement
of a pharmaceutical under the condition that physicians
collect data about its use and effects in daily practice. It
was argued that the availability of data from real-life prac-
tice would provide the opportunity to control the use of
pharmaceuticals. The Board wished to have up-to-date
information about the use of these pharmaceuticals to
check whether the guidelines for prescription were fol-
lowed and to take new measures if necessary.
The databases we studied are presented as policy instru-
ments, but they can best be compared with clinical data-
bases, in that they were initiated by physicians who
developed them for specific medical purposes. The
Growth Hormone database and the antiretroviral drugs
database were initiated by physicians to enable the long-
term follow-up of patients, providing better insight into
the effectiveness and adverse outcomes in clinical practice.
Moreover, CVZ staff was not involved with the set-up of
the databases. They became involved after the plans for
the databases were already made. The Taxol database is an
exception in this respect as the board was involved with
this project from the start. However, the already existing
infrastructure of the Dutch Clinical Cancer Database was
used to develop the Taxol database. In short, the frame-
works for these databases were established by medical
associations.
Results
Providing information about the diffusion of 
pharmaceuticals in clinical practice
To gain insight into the use of the databases, we made an
overview of the policy questions that were supposed to be
answered with the information that would become avail-
able from the databases. On the basis of the study of the
documents and the focus groups, we identified two sets of
policy questions. The first set of questions concerned the
effects of pharmaceuticals in daily practice, and the sec-
ond focused on control of cost and quality.
In several policy documents the need is stressed for
improving the evidence base for the reimbursement deci-
sion. It was suggested that the effects of pharmaceuticals
might be different in clinical practice. As members of the
Committee on Pharmaceutical Care of CVZ (who decide
upon the reimbursement of pharmaceuticals) explained
during interviews, trial data may not reflect clinical prac-
tice because they are collected in a controlled situation
and over too short a period of time. Therefore databases
were perceived as needed to monitor the effectiveness and
safety of the use of pharmaceuticals in clinical practice.
The other recurring policy issue was controlling costs and
quality. The CVZ staff was interested finding out whether
physicians follow the protocols and/or whether new
groups of patients get indicated for these pharmaceuticals.
Working with the databases would allow CVZ staff to
obtain more detailed information on medical practice.
This is because in the case of the growth hormone data-
base, and administrators visit the hospitals and retrieve
the data directly from the medical records. The other data-
bases also contain data from clinical records. In other
words, the databases could provide CVZ staff with clinical
data they otherwise would have no access to, as it would
be inconceivable for CVZ staff to ask hospitals directly to
open their medical archives in order to check the use of
pharmaceuticals.
After reconstructing the main policy questions, we exam-
ined whether these policy questions were answered –
whether data had been retrieved from the databases and
analyzed to decide upon reimbursement or to check the
actual use of the monitored pharmaceuticals.
It is difficult to reconstruct the decisions about the reim-
bursement, as the documents are not public. We have,
however, some evidence that the data were not used.
None of the key informants apparently knew whether the
databases were used for decision making concerning cov-
erage of either of these pharmaceuticals. Most of them
believed that this had not been the case. According to the
owner of the Taxol database, the board could not use the
data for formal purposes as the data set was not yet com-
plete at the time the decision about the reimbursement
was made. Our document analyses confirmed that the
data about the use of Taxol was published six months after
the final decision about coverage was made [22,23].
In our interviews and in the focus group sessions, we
asked CVZ staff members how they used the data to con-Page 3 of 6
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that is was possible to check the use of pharmaceuticals
using these databases. The following quotes are typical
examples of how the staff discussed the use of databases
to control prescription behavior:
respondent 1 "With a database we will know if things go wrong
and we need to intervene. In order to do so we need to have
extra instruments."
respondent 2 "Yeah, the question is whether a database is of
any use. What kind of evidence do we get from the data? Is it
strong enough to make decisions about new interventions?"
Respondent 3 "I think monitoring is extravagantly promoted. It
is nothing. It only means collecting data. That is all. It has
become a bureaucratic duty that will take us a lot of time and
cost a lot of money. And it is nothing."
Both types of policy questions, we can conclude, were not
answered, at least not by the data collected in the data-
base. Some data have been presented to policy makers.
These reports were not made because the CVZ staff asked
for them, but because an annual report was required. As
one of our respondents said reporting data became "a
bureaucratic duty".
Databases and the governance of clinical practice
While the databases were not used to answer policy ques-
tions, they did nevertheless have a profound effect on con-
trolling clinical practice as they facilitated collaboration
between policy makers and physicians.
First, collecting data became an 'obligatory passage point'
for treating patients with a certain drug [24]. As clinical
databases became an instrument for evidence-based pol-
icy, CVZ started to support the development of these data-
bases. They paid for the collection of the data. To enforce
complete data sets, the registration of patients was made a
condition for reimbursement. Before 1998 only academic
centers in the western part of the Netherlands delivered
data for the growth hormone database; after 1998 all phy-
sicians who wanted to treat patients with growth hor-
mone had to participate in the database project. The HIV
database, which was designed as a single centre database,
was also extended into a national database on the basis of
the CVZ policies. For Taxol treatments pharmacists
needed a subsidy; otherwise the hospital had to pay for
the drug itself. To receive the subsidy, they needed to
deliver the clinical data to the centralized database.
Second, all drug-specific databases used explicit protocols
for data collection, so that patients are treated and data are
documented in a standardized manner. The guideline for
using growth hormone is illustrative of this phenomenon
[25]. In contrast to most professional guidelines in the
Netherlands, this guideline does not start with a general
description of growth hormone deficiency. Instead, it
starts with a set of diagnostic criteria. The protocol pro-
vides a detailed description of how a physician should
diagnose growth hormone deficiency and how this diag-
nosis should be checked before the treatment can start.
The guidelines for Taxol and anti-HIV drugs function in a
similar way, as do guidelines for using and monitoring
specific pharmaceuticals. Again just like collecting partic-
ular data, adherence to these guidelines is a prerequisite
for reimbursement.
As a result of the development of the databases these types
of pharmaceuticals are only prescribed by specialized phy-
sicians. Although all general practitioners can basically
prescribe anti-HIV drugs and all pediatricians are allowed
to administer growth hormone, few actually do. Only a
few general practitioners treat patients with AIDS because
most patients are treated in specialized centers. Children
with growth hormone deficiency are also treated less often
in general hospitals by general pediatricians. Increasing
numbers children with this deficiency are treated in spe-
cialized hospitals by specialized pediatricians. According
to the administrators of the two databases for growth hor-
mone and anti HIV drugs, the use of complex guidelines
and registration forms made it more difficult (and cum-
bersome) for general practitioners or pediatricians in gen-
eral hospitals to fulfill all requirements and to get paid for
the drugs.
Paradoxically, the databases in this way enacted a policy
that CVZ had wanted to implement earlier, but which was
faced with serious physician opposition. CVZ wanted to
restrict the prescription of growth hormone, Taxol, and
anti HIV to only (highly) specialized physicians. The phy-
sicians, however, had strong objections to such a condi-
tion. According to the professional medical associations,
physicians should be free to prescribe all drugs. Moreover,
it would be difficult to define criteria for what constitutes
a specialized physician. However, with the introduction
of databases, an informal process of specialization did
occur.
In effect, the deployment of databases can be seen as part
of the establishment of interdisciplinary networks around
the controlled use of specific drugs. The anti HIV drug
database is a case in point [26]. In an internal evaluation
report the possibilities of the database were praised in this
respect. "According to the Health Care Insurance Board,
the (...) project went very well. Thanks to this project, a
network of physicians, pharmacologists and virologists
for the introduction of the anti-HIV drug therapy was
established (...). The Board wishes this network to con-
tinue" [26]. Within the network CVZ is referring to in thisPage 4 of 6
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CVZ is referring to in this quote: physicians, pharmacolo-
gists and virologists. They do not share a professional
background, and they do not work for the same organiza-
tion either. They are part of the network called the 'Net-
work for monitoring the effect on HIV-1 infection of anti-
retro-viral treatment', because they prescribe, deliver and
check certain anti-HIV drugs. Not the patients they treat,
but the drugs they use for the treatment of these patients,
and in effect the data they collect for the central database,
are the major link between them.
Similar networks have been established around growth
hormone. All Dutch pediatrician endocrinologists meet
four times a year in the Advisory group Growth Hormone
(AGH). On their request, the National Registration of
Growth hormone (LRG) analyses the database data. The
LRG for example compared all patients with a partial
growth hormone deficiency and reported the clinical
results of these treatments. Since 1998 such an analysis
has been the basis for several revisions of the guideline.
Draft revisions of the guideline are discussed with all pedi-
atrician-endocrinologists in the Netherlands during their
annual meetings. The purpose of these discussions is to
reach consensus. If consensus is reached, all pediatrician-
endocrinologists receive an update of, or a supplement to
the guideline [19].
As the example of database use shows CVZ is not the
exclusive or dominant site for controlling the use of a cer-
tain drug as the deployment of databases supports the
establishment of interdisciplinary networks around a spe-
cific drug. In all three networks around the drugs we stud-
ied, specific guidelines were used to check if the
pharmaceuticals were prescribed appropriately. Moreo-
ver, as a result of the use of complex guidelines and regis-
tration forms, these types of pharmaceuticals are
prescribed only by specialized physicians. In the networks
using these protocols, collecting data and monitoring the
treatment can hardly be separated.
Discussion
Policy makers hardly use databases. CVZ staff asked for an
infrastructure to collect data about the use of pharmaceu-
ticals in daily clinical practice to check the use of pharma-
ceuticals and to make final decisions about
reimbursement, but they never used the data for these
ends. We demonstrated that the policy questions for
which these databases were established needed no
answers databases could provide. Policy questions are for-
mulated when a new database is started, but these ques-
tions are forgotten the moment the data can be analyzed
when the budget period is over. Rather than setting up or
subsidizing databases to answer specific policy questions,
it seemed that the mere existence of databases was consid-
ered enough from the perspective of policy, i.e. the func-
tion of databases from a policy perspective at first sight is
symbolic rather than substantial (see also [27]).
However, as we showed in this paper, it is too simple to
conceive the 'use' of databases only as retrieving and ana-
lyzing data to answer policy questions. The (policy) ques-
tions needed no answers because by developing these
databases the regulatory authority was, albeit implicitly,
delegated downwards into the network. The deployment
of databases supported the establishment of interdiscipli-
nary networks around a specific drug. In all three net-
works around the drugs we studied, specific guidelines
were used to check if the pharmaceuticals were only pre-
scribed to certain well-defined patient groups. Moreover,
as a result of the use of complex guidelines and registra-
tion forms, these types of pharmaceuticals are prescribed
only by specialized physicians. Thus, the databases and
the protocols that form part of them are fulfilling control
functions that were formerly located within the policy
realm. In this sense, the databases studied here form typi-
cal examples of how information networks become gov-
ernance networks as these networks form mechanisms of
co-governance and self-governance [13].
Delegating regulatory authority solved important prob-
lems for CVZ. As policy makers explained to us, it is diffi-
cult for them to reconsider the reimbursement of a
pharmaceutical on the basis of clinical data. In compari-
son to clinical trial data, still seen as the most important
evidence for policy decisions, the evidence would simply
not be strong enough. Retrospectively, the delegation of
regulatory authority was a better, albeit implicit, strategy
than take top-down measures based upon the data out of
the database. A database can be an effective policy instru-
ment as CVZ, together with physicians, succeeded in
incorporating more and more physicians in their network
(compare Bang [12]). By establishing databases, CVZ was
able to check the use of pharmaceuticals in that they
achieve a degree of compliance from physicians.
Databases are considered to be a new type of instrument
in the progress of 'evidence-based' health policy [1-3].
Usually, the notion of evidence-based policy is framed to
indicate that policymakers should make more use of the
results delivered to them from science [4,5]. The idea that
science and policy should be considered as separate
realms, the one concerned with the production of objec-
tive truth and the other with the production of normative
policies, has proved not to be an adequate description of
actual policy-making practices (see e.g. [28,29]). Our
analysis of the use of databases in Dutch pharmaceutical
policy adds to these insights by showing that their effect
was not so much tied to the data that were delivered to the
policy arena, but rather to the mechanism for data collec-Page 5 of 6
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changed the relations between clinical and policy prac-
tices. Rather than evidence leading to policy, it is the
extension of the networks through which data flow (or do
not flow) that seemed to affect the clinical practice of drug
prescriptions. Taking into account these network charac-
teristics seems to be a promising avenue for the further
analysis of evidence-based policy.
Conclusion
The databases we studied facilitate collaboration between
policy makers and physicians, as they enable quality
assurance by national bodies of professionals. The data-
bases are fulfilling control functions that were formerly
located within the policy realm. Delegation of regulatory
authority downwards into a network of physicians who
control the use of pharmaceuticals, formed around and as
an effect of the databases, seems to be more effective than
centralized control of results on the basis of monitoring
data.
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